Characterization of monocytes-targeted nanocarriers biodistribution in leukocytes in ex-vivo and in-vivo models

Nano Biomedicine and Engineering

Volumn 2, Issue 2, 2010, Pages 91-99

  Cohen Sela, Einat ^a   Chorny, Michael ^b   Gutman, Dikla ^a   Komemi, Sivan ^a   Koroukhov, Nickolay ^a   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Endocytosis; Leukocytes; Liposomes; Monocytes; Nanoparticles (NP); UptakeInternalization

Indexed keywords

EID: 78649325465     PISSN: None     EISSN: 21505578     Source Type: Journal    
DOI: 10.5101/nbe.v2i2.p91-99     Document Type: Article

References (35)

1. Farokhzad OC and Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58: 1456-9.
2. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS and Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008; 83: 761-9.
3. Li SD and Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5: 496-504.
4. Ishida T, Harashima H and Kiwada H. Liposome clearance. Biosci Rep 2002; 22: 197-224.
5. Moghimi SM, Hunter AC and Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19: 311-30.
6. Owens DE, 3rd and Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
7. Alexis F, Pridgen E, Molnar LK and Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505-15.
8. Moghimi SM, Hunter AC and Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318.
9. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD and Golomb G. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release 2008; 132: 84-90.
10. Bakker-Woudenberg IA, Storm G and Woodle MC. Liposomes in the treatment of infections. J Drug Target 1994; 2: 363-71.
11. Danenberg HD, Fishbein I, Gao J, Monkkonen J, Reich R, Gati I, Moerman E and Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002; 106: 599-605.
12. van Rooijen N and Sanders A. Liposome mediated depletion of macrophages:mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 83-93.
13. van Rooijen N and van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 2002; 12: 81-94.
14. Cohen-Sela E, Dangoor D, Epstein H, Gati I, Danenberg HD, Golomb G and Gao J. Nanospheres of a bisphosphonate attenuate intimal hyperplasia. J Nanosci Nanotechnol 2006; 6: 3226-34.
15. Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, Reich R, Danenberg HD and Golomb G. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Controlled Rel 2006; 113: 23-30.
16. Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, Monkkonen J, Gao J, Gathi I, Reich R and Golomb G. Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol 2003; 42: 671-9.
17. Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, Swaminathan RV, Seifert P and Edelman ER. Liposomal alendronate inhibits systemic innate immunity and reduces instent neointimal hyperplasia in rabbits. Circulation 2003; 108: 2798-804.
18. Markovsky E, Koroukhov N and Golomb G. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomed 2007; 2: 545-53.
19. Haber E, Danenberg HD, Koroukhov N, Ron-El R, Golomb G and Schachter M. Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model. Hum Reprod 2009; 24: 398-407.
20. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD and Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release 2009; 133: 90-5.
21. Fessi H, Devissaguet JP, Puisieux F and Thies C. U.S. patent 1992; 5: 528.
22. Chorny M, Polyak B, Alferiev IS, Walsh K, Friedman G and Levy RJ. Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. FASEB J 2007; 21: 2510-9.
23. Szoka F, Jr. and Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980; 9: 467-508.
24. Epstein H, Berger V, Levi I, Eisenberg G, Koroukhov N, Gao J and Golomb G. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Controlled Rel 2007; 117: 322-32.
25. Bucher DJ, Kharitonenkov IG, Zakomirdin JA, Grigoriev VB, Klimenko SM and Davis JF. Incorporation of influenza virus M-protein into liposomes. J Virol 1980; 36: 586-90.
26. Leo E, Contado C, Bortolotti F, Pavan B, Scatturin A, Tosi G, Manfredini S, Angusti A and Dalpiaz A. Nanoparticle formulation may affect the stabilization of an antiischemicprodrug. Int J Pharm 2006; 307: 103-13.
27. Gibaud S, Demoy M, Andreux JP, Weingarten C, Gouritin B and Couvreur P. Cells involved in the capture of nano-particles in hematopoietic organs. J Pharm Sci 1996; 85: 944-50.
28. Zambaux MF, Faivre-Fiorina B, Bonneau F, Marchal S, Merlin JL, Dellacherie E, Labrude P and Vigneron C. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 2000; 21: 975-80.
29. Ke Y and Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptormediated uptake. J Exp Med 1996; 184: 1179-84.
30. Blumenthal R, Weinstein JN, Sharrow SO and Henkart P. Liposome--lymphocyte interaction: saturable sites for transfer and intracellular release of liposome contents. Proc Natl Acad Sci U S A 1977; 74: 5603-7.
31. Leroux JC, Gravel P, Balant L, Volet B, Anner BM, Allemann E, Doelker E and Gurny R. Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles. J Biomed Mater Res 1994; 28: 471-81.
32. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM and Hanlon DJ. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117: 78-88.
33. Zhang JS, Liu F and Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 2005; 57: 689-98.
34. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA and Leenen PJ. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-7.
35. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R and Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-6.